Cipla Limited (NSE:CIPLA)
1,502.80
-51.80 (-3.33%)
Aug 1, 2025, 3:30 PM IST
Triumph Group Revenue
Cipla had revenue of 68.37B INR in the quarter ending June 30, 2025, with 3.20% growth. This brings the company's revenue in the last twelve months to 274.80B, up 6.13% year-over-year. In the fiscal year ending March 31, 2025, Cipla had annual revenue of 272.67B with 6.78% growth.
Revenue (ttm)
274.80B
Revenue Growth
+6.13%
P/S Ratio
4.42
Revenue / Employee
9.07M
Employees
30,313
Market Cap
1,213.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 93.60B |
Apollo Hospitals Enterprise | 217.94B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 232.42B |
Fortis Healthcare | 77.86B |
Aurobindo Pharma | 317.24B |
Alkem Laboratories | 129.65B |
Cipla News
- 17 hours ago - Nifty 50 top losers today, August 1: Sun Pharma, Dr. Reddy’s Laboratories, Adani Enterprises, Cipla and more - Business Upturn
- 2 days ago - Nifty top losers today, July 30: Tata Motors, Hero MotoCorp, Power Grid, Cipla, Bajaj Auto and more - Business Upturn
- 4 days ago - Nifty top gainers today, July 28: Shriram Finance, Cipla, Hero MotoCorp, Asian Paints, Hindustan Unilever and more - Business Upturn
- 4 days ago - Top stocks to buy this week: What's the outlook for Nifty? Check stock recommendations - The Times of India
- 4 days ago - Stocks to watch on brokerages, July 28: Mphasis, Cipla, Kotak Bank, Laurus Labs, IDFC First Bank, Bank of Baorda, SBI Cards, and more in focus - Business Upturn
- 5 days ago - Jefferies maintains hold on Cipla, sets Rs 1,690 target as weak India and US growth offset by strong ROW and margin guidance - Business Upturn
- 5 days ago - Nomura maintains buy on Cipla, sees 18% upside on domestic recovery hopes and new US launches - Business Upturn
- 5 days ago - Goldman Sachs maintains sell on Cipla, cuts target to Rs 1,375 as gRevlimid boost fades despite strong Q1 margin beat - Business Upturn